S&P 500——Nasdaq——Dow Jones——S&P 500——Nasdaq——Dow Jones——S&P 500——Nasdaq——Dow Jones——S&P 500——Nasdaq——Dow Jones——
GSGetStockReport

Loading report…

RESEARCH REPORT

Merck & Company, Inc.

MRK

$149.52

As of 2026-11-01

Research note — 2026-11-01. Educational analysis, not financial advice.

The one-line version

Merck & Company, Inc. trades near $149.52 on a trailing multiple of about 151.0x versus its own 5-year median near 104.2x, against contested Street targets and the usual concentration and execution risks. That's the tension. Everything below is the detail.

That's the tension. Everything below is the detail.

1. What you're paying

NowIts own 5-year medianGap
P/E (trailing)~151.0~104.2+45%
P/E (forward)~16.4——
EPS (TTM)0.99——
Gross margin76.9%——

What that means in plain terms: the gap versus the company's own history is the growth or durability the market is already pricing. It is not automatically wrong — it is the bet.

Fair-value anchors on file:

  • 5-year median P/E multiple: $103.13 — Applies the 5-year median multiple (104.2x) to trailing EPS.
  • Street mean target: $159.83 — Average published analyst target.
  • Street target midpoint: $145.50 — Midpoint of $105.00–$186.00 published range.

Street targets run from $105.00 to $186.00. A wide spread means the name is contested, not consensus.

2. What the bulls are counting on

  • MRK Q3 deep dive: oncology launches, clinical pipeline advances, and margin headwinds
  • How market participants Are Reacting To Moderna Stock Phase 3 Melanoma Vaccine Data
  • Elon Musk Says Eli Lilly Has ‘Some Banger Drugs Coming Out’ After CEO Dave Ricks Bets Against Vinod Khosla's Big Biotech Skepticism

Sign up free to read the full analysis

Bull case, bear case, assumptions, and what to watch next.

3. What the bears see

  • Merck (MRK) Stock Rallies As Q3 Earnings Ease Profit Squeeze
  • Why Merck Stock Flew Higher on Friday
  • JP Morgan Maintains Overweight on Merck & Co, Raises Price Target to $175

Sign up free to read the full analysis

Bull case, bear case, assumptions, and what to watch next.

4. What would have to be true

For the stock to justify ~151.0x rather than its 5-year ~104.2x, roughly all of the following need to neutral:

  1. Growth or margin durability shows up in the next several reports, not just in narrative.
  2. Key revenue concentrations survive competitive and regulatory pressure.
  3. Execution on the current product or services cycle stays on schedule.
  4. The Street target range compresses as results clarify the contested assumptions.

Ask yourself honestly: how many of those would you bet on individually? Multiply your answers together.

Sign up free to read the full analysis

Bull case, bear case, assumptions, and what to watch next.

5. What to watch next

  • Next earnings date: 1793277000
  • Trailing and forward multiples versus the company's own history
  • Segment growth rates in the next 10-Q / earnings release
  • Material Form 4 and 13F changes
  • Whether the Street high-to-low target spread narrows or widens

Sign up free to read the full analysis

Bull case, bear case, assumptions, and what to watch next.

6. What this note does not do

It doesn't tell you to buy or sell. It won't, ever.

You have the valuation in context, the strongest version of both cases, and the specific assumptions the current price depends on. What you do with that depends on your time horizon, your existing exposure, your risk tolerance, and what else you could do with the money — none of which we know.

If you want someone to tell you what to do, you want a licensed financial adviser, and that is a genuinely reasonable thing to want.

Educational and informational purposes only. Not investment advice and not a recommendation to buy or sell any security. GetStockReport is not a registered investment adviser. Figures are as of 2026-11-01 and go stale quickly — verify against primary sources before acting. All investments carry risk including loss of principal. Past performance does not guarantee future results.

8. Analyst ratings & targets

No recent activity

Analyst opinions change frequently. Past upgrades do not predict future returns.

9. Important news

News headlines are reported as-is. Verify important claims with original sources.

10. Insider Form 4 activity

DateExecutiveActionSharesValue
Nov 1, 2026DIAZ PAUL JSell613.073$91,666.67

Form 4 filings are routine transactions. Scheduled sales (10b5-1 plans) are normal and not signals.

11. Institutional 13F holdings

FundSharesPositionChange
Vanguard Group229,006,389$24.1B—
State Street120,413,256$15.6B—
BlackRock75,200$9.3B—
BlackRock Institutional Trust12,473,411$734.3M—

These are 45-day lagged filings (SEC requirement). Position changes happened in the past.

12. Earnings this week

No recent activity

Earnings dates are estimates and may shift. EPS estimates are consensus, not predictions.

← Browse all reports